ST欧阳昆汀(被困Hims版)

In this episode of the Hims house podcast (recorded in mid-to-late June), Needham's Chief Analyst Ryan McDonald was invited. He focuses on analyzing HIMS and its related businesses, particularly delving into peptides, GLP-1 drugs, and other related fields. Ryan holds a Buy rating on HIMS with a $35 target price. The discussion covers FDA regulatory dynamics, market size, industry competition, core business assessments, and future outlook...

The interviewee for this episode's (July 6th) podcast is Hims and Hers' co-founder and CEO Andrew Dudham. The interview revolves around the current state of the U.S. healthcare industry, the original intent and development journey behind the founding of $Hims & Hers Health(HIMS.US), the transformation of online healthcare, and the explosive growth and regulatory challenges of the GLP-1 drug market...

In the early morning of July 11th, Beijing time, a letter sent by the U.S. PSM (Partnership for Safe Medicines, which describes itself in the document as a non-profit organization focused on patient safety and combating counterfeit and non-compliant drugs) to the FDA was disclosed. The letter urges the FDA to reject the formulation of seven peptide compounds under review. It's uncertain whether this document is the reason for Hims' crash this week, but the well-connected short sellers must have received the news in advance (the letter was sent on July 1st, Eastern Time, but only disclosed on July 10th)...

$Hims & Hers Health(HIMS.US) started recruiting for peptide-related positions such as Project Manager, Peptide API Operations on July 4th. I have a question❓ The PCAC review on July 23-24 hasn't even started yet. Whether it passes or gets rejected, nobody knows. Why is Brother Du already recruiting for large-scale raw material production personnel? He's not waiting for the review results before acting, but is already taking action as if he's certain the peptide era is about to arrive...

This video focuses on the long-term investment thesis of Hims & Hers. Guest David Wells, from the perspective of a former Netflix CFO, discusses Hims' potential in telemedicine, AI, wearables, weight loss business, subscription models, and consumer healthcare platformization. He believes the market may be underestimating Hims' long-term vision: it's not just an opportunistic company selling ED, hair loss, or GLP-1 weight loss products, but is attempting to integrate technology, healthcare services, and direct-to-consumer experience...

Hims has secured a receivables purchase facility of up to $400 million from JPMorgan, further enhancing its cash flow capabilities and providing funding support for future business expansion. However, this is not an additional equity financing, nor is it the issuance of new debt...

Needham 分析师 Ryan MacDonald 表示，FDA 工作人员此前提出的建议 “确实有些出乎意料”，但这并不意味着最终被否决。他在 Hims 投资者社区中表示：“这并不是这件事的终点。” 他补充称，虽然目前获批概率可能略有下降，但他仍然认为最终会获得批准...

Yesterday's document was just a preliminary opinion. The PCAC committee will provide recommendations to the FDA at the meeting, and the FDA will make a final decision after considering the PCAC's input. The FDA just added 8 new panel members, most of whom are affiliated with companies that promote or prescribe peptide products. Therefore, the committee has now effectively been "stacked" to be more inclined to give favorable recommendations for peptides. PCAC is purely advisory. Its vote is not binding. The FDA still retains the final decision-making authority. Theoretically...

In the 71st episode of "Hims House," Jonathan Stern engaged in an in-depth conversation with hedge fund manager Ignacio Canto. Ignacio is the founder and portfolio manager of X-Square Capital, which held over 420,000 shares of Hims as of the first quarter. Canto traced his interest in the company over the years, stemming from his personal experience using the product and the professional perspective of his late father, a urologist...

New York, June 25 (Reuters) — Investors and analysts say remote healthcare provider $Hims & Hers Health(HIMS.US) may benefit next year from a trend of employers stopping coverage for weight-loss drugs. These drugs include Novo Nordisk's Wegovy, Eli Lilly's Zepbound, and Foundayo, among others, as companies aim to control costs. Industry experts say the surge in usage of such drugs has driven up employers' healthcare costs. Some employers plan to inform employees in 2027...

This video delves into the current state and future development of the U.S. peptide drug market. With the FDA about to hold an important meeting to review relevant policies, the peptide track is expected to achieve regulatory relaxation, driving explosive growth in market size. At the same time, peptide products lacking patent protection are causing shocks within the industry, prompting large pharmaceutical manufacturers and compounding pharmacies to reassess their market strategies. Overall, peptide drugs are at the forefront of medical innovation, and their development trends deserve continued attention.